Rosuvastatin is a selective and competitive inhibitor of HMGCoA reductase. HMGCoA reductase is the rate-limiting enzyme that converts 3-hydroxymethylglutaryl-CoA to mevalonate (the precursor of cholesterol). Rosuvastatin produces its lipid modification effect in two ways. First, it increases the number of liver low-density lipoprotein receptors on the cell surface to enhance the absorption and catabolism of low-density lipoprotein. Secondly, Rosuvastatin inhibits liver VLDL synthesis and reduces the total number of VLDL and LDL particles.
Dosage of Rosuva 5
The significant drug interaction for rosuvastatin is cyclosporine: combined use will increase rosuvastatin exposure. The dose of rosuvastatin should be limited to 5 mg once a day.
Gemfibrosil: Conjoint use should be avoided. If used
together, the dose of rosuvastatin should be limited to 10 mg once a day.
Lopinavir / Ritonavir or Atazanavir / Ritonavir:
Combination use will increase rosuvastatin exposure. The dose of rosuvastatin
should be 10 mg per day.
Coumarin Anticoagulant: This combination expands the
International Normalized Ratio (INR). Before starting rosuvastatin, a stable
INR should be reached. After starting or changing rosuvastatin therapy, the INR
should be monitored frequently until it stabilizes.
Concomitant lipid-lowering therapy: use with fibrates and niacin products may increase the risk of effects on skeletal muscle.
Rosuvastatin can be taken with or without food, at any time of day
The remarkable interaction of Rosvastatin drugs is cyclosporine: the combination increases exposure to loss. The doses of bestatin should be limited to 5 mg per day.
Gemfibrosil: combinations should be avoided. When
used together, the dose of the loss of vastatin should be limited to 10 mg
ROPINAVIR / RINGGA / ATAMAVIL / RINTEA building: The
combination increases exposure to loss. The doses of the ovascatin must
have up to 10 mg per day.
Coumarin Anticoagulant: The combination extends an
international standardization ratio (INR). Before starting the loss of
vastatin, you must achieve a stable INR. INR must be monitored frequently until
it is stable when starting or changing the loss of vastatin therapy.
Combined lipid supply therapy: The use of fibrate and niacin products may increase the risk of skeletal muscle effect.
If is known to be allergic to product ingredients, ban rosuvastatin Liver disease, which may include persistent and unexplained elevated liver transaminase levels Pregnant women and women who may become pregnant Nursing mothers
Rosuvastatin is generally well tolerated. The most frequent adverse events thought to be related to Rosuvastatin were headache, myalgia, constipation, asthenia, abdominal pain and nausea.
The safety of women has not been established during pregnant women. It is not known if Lavastatin is excreted by human milk.
Effects on skeletal muscle (eg, myopathy and rhabdomyolysis): risk increases with the use of 40 mg doses, advanced age (> 65 years), hypothyroidism, renal failure, and interactions with cyclosporine, lopinavir / ritone Weir, atazanavir/ritonavir, or some Other lipid-lowering drugs are used in combination. Patients should be advised to report unexplained muscle pain, tenderness, or weakness early. If signs or symptoms appear, rosuvastatin can be stopped.
Abnormal liver enzymes and monitoring: Continuous elevation of liver transaminases may occur. Liver enzymes should be monitored before and during treatment.
Other Anti-anginal & Anti-ischaemic drugs, Statins
Keep below 30oC temperature, protected from light & moisture. Keep out of the reach of children.